Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection
Douglas J. Haney(PaxVax (United States)), Jason B. Harris(Harvard University), Wilbur H. Chen(University of Maryland, Baltimore), Marcelo B. Sztein(University of Maryland, Baltimore), Myron M. Levine(University of Maryland, Baltimore), Michael Lock(PaxVax (United States)), Marc Gurwith(Ligand Pharmaceuticals (United Kingdom)), Caroline E. Lyon(University of Vermont), Mitchell B. Cohen(Centre Hospitalier Universitaire Sainte-Justine), Glenn Ishioka(PaxVax (United States)), Jakub K. Simon(University of Maryland, Baltimore), Beth D. Kirkpatrick(University of Vermont)
Cited by 28
Related Papers
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.
|PubMed|1999|1.3k
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
|Nature|1987|503
Serum Levels of the Proinflammatory Cytokines Interleukin-1 Beta (IL-1β), IL-6, IL-8, IL-10, Tumor Necrosis Factor Alpha, and IL-12(p70) in Malian Children with Severe<i>Plasmodium falciparum</i>Malaria and Matched Uncomplicated Malaria or Healthy Controls
|Infection and Immunity|2004|447
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road
|Nature Reviews Microbiology|2007|372
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans
|Infection and Immunity|1997|251